Literature DB >> 7216427

Inhibition of lymphocyte proliferative responses by ribavirin.

D L Peavy, W C Koff, D S Hyman, V Knight.   

Abstract

When added to cultures of human peripheral blood lymphocytes, ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) inhibited antigen- and mitogen-induced proliferative responses as determined by [3H]thymidine incorporation. Dose-dependent suppressive effects were obtained when concentrations of 5 to 60 microgram of ribavirin per ml were added at culture initiation or up to 96 h thereafter. Ribavirin inhibited [3H]uridine and [3H]leucine incorporation by concanavalin A-activated and normal lymphocytes although not as severely as deoxyribonucleic acid synthesis. The capacity of ribavirin to interfere with lymphoproliferative responses was entirely reversed by guanosine and, to a lesser extent, by adenosine and xanthosine. These studies demonstrate that ribavirin is a reversible inhibitor of lymphocyte nucleic acid synthesis and suggest that the drug may be immunosuppressive when administered in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7216427      PMCID: PMC551161          DOI: 10.1128/iai.29.2.583-589.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Antiviral, immunosuppressive and antitumour effects of ribavirin.

Authors:  C W Potter; J P Phair; L Vodinelich; R Fenton; R Jennings
Journal:  Nature       Date:  1976-02-12       Impact factor: 49.962

2.  Efficacy of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide against influenza virus infections in mice.

Authors:  F E Durr; H F Lindh; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

3.  Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides.

Authors:  J T Witkowski; R K Robins; R W Sidwell; L N Simon
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

4.  Inhibitors of inosinate dehydrogenase activity in Ehrlich ascites tumor cells in vitro.

Authors:  C M Smith; L J Fontenelle; H Muzik; A R Paterson; H Unger; L W Brox; J F Henderson
Journal:  Biochem Pharmacol       Date:  1974-10-01       Impact factor: 5.858

5.  Cell-mediated immune response to influenza virus infections in mice.

Authors:  G Cambridge; J S Mackenzie; D Keast
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

6.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

8.  Ribavirin: efficacy in the treatment of murine autoimmune disease.

Authors:  L W Klassen; D R Budman; G W Williams; A D Steinberg; N L Gerber
Journal:  Science       Date:  1977-02-25       Impact factor: 47.728

9.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

10.  Therapeutic effects of small-particle aerosols of ribavirin on parainfluenza (sendai) virus infections of mice.

Authors:  E W Larson; E L Stephen; J S Walker
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

View more
  9 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  Comparison of the chronic effects of ribavirin and caffeic acid phenethyl ester (CAPE) on pancreatic damage and hepatotoxicity.

Authors:  Sedat Motor; Harun Alp; Serkan Senol; Neslihan Pınar; Vicdan Köksaldı Motor; Ibrahim Kaplan; Ayşe Alp; Cumali Gökçe
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 3.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Authors:  Eleanor Barnes; Mariolina Salio; Vincenzo Cerundolo; Joanne Medlin; Shona Murphy; Geoffrey Dusheiko; Paul Klenerman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

6.  Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

Authors:  J J Kirsi; P A McKernan; N J Burns; J A North; B K Murray; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Selective inhibition of functional lymphocyte subpopulations by ribavirin.

Authors:  C N Powers; D L Peavy; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

8.  Inhibitory effects of compounds from Phyllanthus amarus on nitric oxide production, lymphocyte proliferation, and cytokine release from phagocytes.

Authors:  Ibrahim Jantan; Menaga Ilangkovan; Khairana Husain; Kok Meng Chan
Journal:  Drug Des Devel Ther       Date:  2016-06-09       Impact factor: 4.162

9.  Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production).

Authors:  Silvia Sookoian; Gustavo Castaño; Diego Flichman; Jerónimo Cello
Journal:  Ann Hepatol       Date:  2004 Jul-Sep       Impact factor: 2.400

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.